Transgene
Transgene is a pioneering biotech company focused on designing and developing innovative immunotherapies against cancer. They leverage advanced genetic engineering and artificial intelligence technologies to create personalized cancer vaccines and oncolytic viruses, aiming to push the boundaries of immunotherapy and create treatments to fight cancers.
Industries
Nr. of Employees
large (251-1000)
Transgene
400 Boulevard Gonthier d’Andernach, Parc d'Innovation, CS80166, 67405 Illkirch Graffenstaden Cedex, France
Patents
Products
Individualized therapeutic cancer vaccine (clinical-stage)
A clinical-stage individualized therapeutic vaccine program based on patient-specific tumor mutations and AI-informed neoantigen selection; evaluated in randomized Phase I/II studies.
Oncolytic virus platform and armed oncolytic candidates (clinical-stage)
Oncolytic virus platform capable of tumor-targeted lysis and microenvironment modulation, with candidates engineered to express therapeutic payloads (e.g., antibodies, cytokines); programs are in clinical development.
Viral vector vaccine research programs for infectious diseases
Research programs using multivalent adenovirus- and MVA-based vectors to induce cellular immune responses against viral pathogens, reported in peer-reviewed publications.
Individualized therapeutic cancer vaccine (clinical-stage)
A clinical-stage individualized therapeutic vaccine program based on patient-specific tumor mutations and AI-informed neoantigen selection; evaluated in randomized Phase I/II studies.
Oncolytic virus platform and armed oncolytic candidates (clinical-stage)
Oncolytic virus platform capable of tumor-targeted lysis and microenvironment modulation, with candidates engineered to express therapeutic payloads (e.g., antibodies, cytokines); programs are in clinical development.
Viral vector vaccine research programs for infectious diseases
Research programs using multivalent adenovirus- and MVA-based vectors to induce cellular immune responses against viral pathogens, reported in peer-reviewed publications.
Services
Co-development and research collaborations with academic and industry partners to advance viral-based immunotherapies and vaccine platforms.
Co-development and research collaborations with academic and industry partners to advance viral-based immunotherapies and vaccine platforms.
Expertise Areas
- Personalized cancer vaccine development
- Oncolytic virus engineering
- Viral vector vaccine platforms
- Early-phase clinical trial execution
Key Technologies
- Neoantigen prediction and selection
- AI / machine learning for antigen prioritization
- Viral genome engineering
- Oncolytic virus platforms
News & Updates
Update on clinical results of BT-001 presented at ESMO 2025.
Appointment of Emmanuelle Quilès as independent director.
Initial patient selection for Phase II trial of TG4050 in operable head and neck cancer.
Study on the evaluation of Transgene's new oncolytic virus platform using xCELLigence RTCA eSight.
Results from a Phase I trial of TG6002 in liver metastases.
Phase I trial results of TG4050 in head and neck cancer.
Update on clinical results of BT-001 presented at ESMO 2025.
Appointment of Emmanuelle Quilès as independent director.
Initial patient selection for Phase II trial of TG4050 in operable head and neck cancer.
Study on the evaluation of Transgene's new oncolytic virus platform using xCELLigence RTCA eSight.
Results from a Phase I trial of TG6002 in liver metastases.
Phase I trial results of TG4050 in head and neck cancer.